GlobeNewsWire
04 Sept 2026, 13:51 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
EyePoint's Phase 3 LUGANO clinical trial for DURAVYU failed to meet its prespecified primary endpoint for the treatment of wet age-related macular degeneration. — Failure of a pivotal Phase 3 trial typically eliminates the primary path to regulatory approval and commercialization for the drug candidate.
-1.00EyePoint's stock price plummeted over 66% following the announcement of the clinical trial results. — A massive price drop confirms the market's view of the trial failure as a catastrophic loss of company valuation.
-0.80Law firm Kessler Topaz Meltzer & Check is investigating EyePoint for potential violations of federal securities laws on behalf of investors. — The prospect of securities litigation creates additional legal liability and financial overhang for the company.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
13h ago
